Cargando…

The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial

OBJECTIVE: Vitamin D deficiency is quite common among end-stage renal disease (ESRD) patients, and Vitamin D administration could reduce morbidity and mortality in these patients through different mechanisms. Cardiovascular diseases are the most common cause of mortality in these patients that are c...

Descripción completa

Detalles Bibliográficos
Autores principales: Naeini, Afsoon Emami, Moeinzadeh, Firouzeh, Vahdat, Sahar, Ahmadi, Akbar, Hedayati, Zahra Parin, Shahzeidi, Safoora
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348851/
https://www.ncbi.nlm.nih.gov/pubmed/28331861
http://dx.doi.org/10.4103/2279-042X.200994
_version_ 1782514338008924160
author Naeini, Afsoon Emami
Moeinzadeh, Firouzeh
Vahdat, Sahar
Ahmadi, Akbar
Hedayati, Zahra Parin
Shahzeidi, Safoora
author_facet Naeini, Afsoon Emami
Moeinzadeh, Firouzeh
Vahdat, Sahar
Ahmadi, Akbar
Hedayati, Zahra Parin
Shahzeidi, Safoora
author_sort Naeini, Afsoon Emami
collection PubMed
description OBJECTIVE: Vitamin D deficiency is quite common among end-stage renal disease (ESRD) patients, and Vitamin D administration could reduce morbidity and mortality in these patients through different mechanisms. Cardiovascular diseases are the most common cause of mortality in these patients that are caused by vascular injuries. Intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) are vascular inflammation indicators. The goal of this study is to find the effect of Vitamin D administration on ICAM-1 and VCAM-1 serum levels in ESRD patients on hemodialysis. METHODS: The current study is a double-blind, randomized, placebo-controlled clinical trial on 64 patients in two groups of control and treatment. Serum levels of Vitamin D, ICAM-1, and VCAM-1 were measured before and after the study. Treatment group was treated with Vitamin D pearls while control group underwent treatment with placebo pearls. Average serum levels of Vitamin D, ICAM, and VCAM were measured in both groups before and after the study and were analyzed by ANOVA, paired t-test, and Chi-square test using SPSS software. FINDINGS: Sixty-four ESRD patients were recruited for this study consisting of 32 male and 32 female subjects within the ages of 18 and 76 years. The change in serum level of Vitamin D was significant in treatment group (P = 0.001) but not in control group (P > 0.05). Serum levels of ICAM and VCAM also changed significantly in treatment group (P = 0.001) but not in control group (P > 0.05) CONCLUSION: Based on the findings of this study, it could be said that Vitamin D administration in ESRD patients may increase serum level of Vitamin D up to four times. It also reduces serum levels of ICAM and VCAM which might improve the vascular condition of these patients.
format Online
Article
Text
id pubmed-5348851
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-53488512017-03-22 The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial Naeini, Afsoon Emami Moeinzadeh, Firouzeh Vahdat, Sahar Ahmadi, Akbar Hedayati, Zahra Parin Shahzeidi, Safoora J Res Pharm Pract Original Article OBJECTIVE: Vitamin D deficiency is quite common among end-stage renal disease (ESRD) patients, and Vitamin D administration could reduce morbidity and mortality in these patients through different mechanisms. Cardiovascular diseases are the most common cause of mortality in these patients that are caused by vascular injuries. Intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM) are vascular inflammation indicators. The goal of this study is to find the effect of Vitamin D administration on ICAM-1 and VCAM-1 serum levels in ESRD patients on hemodialysis. METHODS: The current study is a double-blind, randomized, placebo-controlled clinical trial on 64 patients in two groups of control and treatment. Serum levels of Vitamin D, ICAM-1, and VCAM-1 were measured before and after the study. Treatment group was treated with Vitamin D pearls while control group underwent treatment with placebo pearls. Average serum levels of Vitamin D, ICAM, and VCAM were measured in both groups before and after the study and were analyzed by ANOVA, paired t-test, and Chi-square test using SPSS software. FINDINGS: Sixty-four ESRD patients were recruited for this study consisting of 32 male and 32 female subjects within the ages of 18 and 76 years. The change in serum level of Vitamin D was significant in treatment group (P = 0.001) but not in control group (P > 0.05). Serum levels of ICAM and VCAM also changed significantly in treatment group (P = 0.001) but not in control group (P > 0.05) CONCLUSION: Based on the findings of this study, it could be said that Vitamin D administration in ESRD patients may increase serum level of Vitamin D up to four times. It also reduces serum levels of ICAM and VCAM which might improve the vascular condition of these patients. Medknow Publications & Media Pvt Ltd 2017 /pmc/articles/PMC5348851/ /pubmed/28331861 http://dx.doi.org/10.4103/2279-042X.200994 Text en Copyright: © 2017 Journal of Research in Pharmacy Practice http://creativecommons.org/licenses/by-nc-sa/3.0 This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.
spellingShingle Original Article
Naeini, Afsoon Emami
Moeinzadeh, Firouzeh
Vahdat, Sahar
Ahmadi, Akbar
Hedayati, Zahra Parin
Shahzeidi, Safoora
The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial
title The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial
title_full The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial
title_fullStr The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial
title_full_unstemmed The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial
title_short The Effect of Vitamin D Administration on Intracellular Adhesion Molecule-1 and Vascular Cell Adhesion Molecule-1 Levels in Hemodialysis Patients: A Placebo-controlled, Double-blinded Clinical Trial
title_sort effect of vitamin d administration on intracellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in hemodialysis patients: a placebo-controlled, double-blinded clinical trial
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348851/
https://www.ncbi.nlm.nih.gov/pubmed/28331861
http://dx.doi.org/10.4103/2279-042X.200994
work_keys_str_mv AT naeiniafsoonemami theeffectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT moeinzadehfirouzeh theeffectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT vahdatsahar theeffectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT ahmadiakbar theeffectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT hedayatizahraparin theeffectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT shahzeidisafoora theeffectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT naeiniafsoonemami effectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT moeinzadehfirouzeh effectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT vahdatsahar effectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT ahmadiakbar effectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT hedayatizahraparin effectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial
AT shahzeidisafoora effectofvitamindadministrationonintracellularadhesionmolecule1andvascularcelladhesionmolecule1levelsinhemodialysispatientsaplacebocontrolleddoubleblindedclinicaltrial